Prandin (Repaglinide)–oral drug for treating type 2 diabetes mellitus
General information
Prandin medication is prescribed for treating type 2 diabetes mellitus (non-insulin-dependent diabetes mellitus). Its generic name is repaglinide. Sold in the USA as Prandin, repaglinide is supplied by Novo Nordisk. Prandin medicine is used in combination with a special diet and exercise in adults who cannot manage diabetes by diet, exercise, or anti-diabetic medications alone.  Prandin can be used in combination with other anti-diabetic drugs
PRANDIN Rx
Generic Name and Formulations:
Repaglinide 0.5mg, 1mg, 2mg; tabs.

Company:
Novo Nordisk
Indications for PRANDIN:
Adjunct to diet and exercise in type 2 diabetes, as monotherapy or with metformin or thiazolidinediones.

Adult:
Take within 30 minutes before meals (skip dose if meal is skipped; add dose if meal is added). Treatment-naive, or HbA1c <8%, or severe renal dysfunction (CrCl 20–40mL/min): initially 0.5mg with 2–4 meals daily. Previously treated with antidiabetic agents and HbA1c ≥8%: initially 1–2mg with 2–4 meals daily. For both: titrate by doubling dose at intervals of at least 1 week; range 0.5–4mg with 2–4 meals daily; max 16mg/day. Hemodialysis or CrCl <20mL/min: not recommended.

Children:
Not recommended.

Contraindications:
Type 1 diabetes. Diabetic ketoacidosis. Concomitant gemfibrozil.

Warnings/Precautions:
Not for use with NPH-insulin (serious cardiovascular events possible). Elderly, debilitated, malnourished, or adrenal, pituitary, hepatic or severe renal insufficiency: increased risk of hypoglycemia; titrate more slowly. Stress. Monitor for initial effect and for secondary failure. Pregnancy (Cat.C): consider using insulin instead. Nursing mothers: not recommended.

Interactions:
See Contraindications. Potentiated by gemfibrozil. β-blockers, alcohol, other antidiabetic agents increase risk of hypoglycemia. May be potentiated by CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, clarithromycin), CYP2C8 inhibitors (eg, trimethoprim, montelukast, deferasirox), OATP1B1 inhibitors (eg, cyclosporine), and by other highly protein-bound drugs (eg, NSAIDs, salicylates, sulfonamides), chloramphenicol, coumarins, probenecid, MAOIs. May be antagonized by other CYP3A4 inducers (eg, carbamazepine, rifampin, barbiturates), isoniazid, nicotinic acid, phenytoin, diuretics, corticosteroids, phenothiazines, sympathomimetics, calcium channel blockers, estrogens, oral contraceptives, thyroid drugs, others. β-blockers may mask hypoglycemia.

Pharmacological Class:
Meglitinide analogue.

Adverse Reactions:
Hypoglycemia, upper respiratory infection, headache, diarrhea, constipation, arthralgia, back or chest pain. Oral antidiabetics may increase risk of cardiovascular mortality; myocardial ischemia (w. NPH-insulin).

How Supplied:
Tabs—100, 500, 1000